Initial Investment



Clinical Decision AI

Optellum was founded so that every lung cancer patient is diagnosed and treated at the earliest possible stage, and so has the best possible chance of being cured, whilst reducing unnecessary interventions for the millions who don’t need treatment. It redefines how early lung disease should be intercepted, enabling every clinician in every hospital to manage their patients in the optimal way. Optellum’s solution is based on artificial intelligence and machine learning technologies applied to the world’s largest clinical dataset.

IQ Capital invested in Optellum at Seed stage in 2019.